Drug Trial Radar · NCT06131554
A Clinical Trial to Evaluate the Immunogenicity and Safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in Adults Aged 18 to 55 Years
Last checked: Nov 19, 2026Latest source record: Aug 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,480
Actual
Start
Mar 20, 2024
Primary completion
Jul 12, 2024
Study completion Jun 4, 2025
Sponsor
- Lead sponsor
- CanSino Biologics Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a multicenter, randomized, double-blinded, positive controlled study to evaluate the lot-to-lot consistency, immunogenicity and safety of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) in adults aged 18 to 55 years. Subjects will be randomized to receive investigational Lot 1, Lot 2, Lot 3 vaccine or control vaccine in a 1:1:1:1 ratio, with the subjects in experimental group randomly and equally assigned to three different batches of MCV4 for single-dose vaccination.
Conditions
- Meningococcal Meningitis
Interventions
batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4)Biological
1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection
batch 2 of MCV4Biological
1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection
batch 3 of MCV4Biological
1 dose of Menhycia (0.5ml) on Day 0, Intramuscular injection
Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate VaccineBiological
1 dose of Menactra (0.5ml) on Day 0, Intramuscular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- The geometric mean titer (GMT) of serogroup A, C, Y and W135 meningococcal rSBA titer in all participants.Time frame: Day 30 post vaccination
- The seroconversion rate of serogroup A, C, Y, and W135 meningococcal rSBA titer.Time frame: Day 30 post vaccination
- The incidence of adverse reactions (ARs) in all participants.Time frame: Within 7 days post vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Husada Utama Hospital
Surabaya, Indonesia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.